Rojas, J., de Lazzari, E., Negredo, E., Domingo, P., Tiraboschi, J., Ribera, E., Abdulghani, N., Puig, J., Mateo, M. G., Podzamczer, D., Gutierrez, M. M., Paredes, R., Clotet, B., Gatell, J. M., Blanco, J. L., Martínez, E., & , (2021). efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial. Lancet, 8(8), e463–e473. http://access.bl.uk/ark:/81055/vdc_100139602430.0x000002